Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2021

Open Access 01-12-2021 | Hypertension | Research

Ameliorated biomechanical properties of carotid arteries by puerarin in spontaneously hypertensive rats

Authors: Xiaoxia Fang, Sheng Dong, Yun Wu, Yun He, Min Lu, Dandan Shi, Na Feng, Songhe Yin, Yan Jiang, Anhua Zhang, Yan Ding, Qiufang Zhang, Junming Tang, Wenjun Zhang, Xiju He

Published in: BMC Complementary Medicine and Therapies | Issue 1/2021

Login to get access

Abstract

Background

An emerging body of evidence indicates that puerarin (PUE) plays an important role in the treatment of angina pectoris, myocardial ischemia-reperfusion injury, hypertension and other cardiovascular diseases, but how PUE affects the vascular remodeling of hypertensive rats has not been reported yet. This study aimed to investigate the effect and mechanism of PUE on carotid arteries of spontaneously hypertensive rats (SHR) to provide the basis for the clinical application of PUE.

Methods

Thirty male SHR and six male Wistar Kyoto rats (WKY) aged 3 months were used in this study, SHR rats were randomly divided into 5 groups, PUE(40 or 80 mg/kg/d, ip) and telmisartan (TELMI) (30 mg/kg/d, ig) were administrated for 3 months. We use DMT myography pressure-diameter system to investigate biomechanical properties of carotid arteries, 10 μM pan-classical transient receptor potential channels (TRPCs) inhibitor SKF96365, 200 nM specific TRPC6 inhibitor SAR7334 and 100 μM Orai1 inhibitor ANCOA4 were used in the mechanical test.

Results

PUE can significantly decrease systolic and diastolic blood pressure, long-term administration of PUE resulted in a mild reduction of thickness and inner diameter of carotid artery. PUE ameliorate NE-response and vascular remodeling mainly through inhibiting TRPCs channel activities of VSMC.

Conclusion

PUE can ameliorate biomechanical remodeling of carotid arteries through inhibiting TRPCs channel activities of VSMC in spontaneously hypertensive rats.
Appendix
Available only for authorised users
Literature
4.
go back to reference Hu W, Zhang Q, Yang X, Wang Y, Sun L. Puerarin inhibits C-reactive protein expression via suppression of nuclear factor kappaB activation in lipopolysaccharide-induced peripheral blood mononuclear cells of patients with stable angina pectoris. Basic Clin Pharmacol Toxicol. 2010;107:637–42.CrossRef Hu W, Zhang Q, Yang X, Wang Y, Sun L. Puerarin inhibits C-reactive protein expression via suppression of nuclear factor kappaB activation in lipopolysaccharide-induced peripheral blood mononuclear cells of patients with stable angina pectoris. Basic Clin Pharmacol Toxicol. 2010;107:637–42.CrossRef
8.
go back to reference Gang C, Qiang C, Xiangli C, Shifen P, Chong S, Lihong L. Puerarin suppresses angiotensin II-induced cardiac hypertrophy by inhibiting NADPH oxidase activation and oxidative stress-triggered AP-1 signaling pathways. J Pharm Pharm Sci. 2015;18(2):235–48. https://doi.org/10.18433/J3N318.CrossRefPubMed Gang C, Qiang C, Xiangli C, Shifen P, Chong S, Lihong L. Puerarin suppresses angiotensin II-induced cardiac hypertrophy by inhibiting NADPH oxidase activation and oxidative stress-triggered AP-1 signaling pathways. J Pharm Pharm Sci. 2015;18(2):235–48. https://​doi.​org/​10.​18433/​J3N318.CrossRefPubMed
14.
go back to reference Zhang GQ, Hao XM, Dai DZ, Fu Y, Zhou PA, Wu CH. Puerarin blocks Na+ current in rat ventricular myocytes. Acta Pharmacol Sin. 2003;24(12):1212–6.PubMed Zhang GQ, Hao XM, Dai DZ, Fu Y, Zhou PA, Wu CH. Puerarin blocks Na+ current in rat ventricular myocytes. Acta Pharmacol Sin. 2003;24(12):1212–6.PubMed
16.
go back to reference Guo XG, Chen JZ, Zhang X, Xia Q. Effect of puerarin on L-type calcium channel in isolated rat ventricular myocytes. Zhongguo Zhong Yao Za Zhi. 2004;29(3):248–51.PubMed Guo XG, Chen JZ, Zhang X, Xia Q. Effect of puerarin on L-type calcium channel in isolated rat ventricular myocytes. Zhongguo Zhong Yao Za Zhi. 2004;29(3):248–51.PubMed
17.
19.
go back to reference Cheng H, Chou C, Liang W, Kuo C, Shieh P, Wang J, et al. Effects of puerarin on intracellular Ca(2+) and cell viability of MDCK renal tubular cells. Environ Toxicol Pharmacol. 2017;52:83–9.CrossRef Cheng H, Chou C, Liang W, Kuo C, Shieh P, Wang J, et al. Effects of puerarin on intracellular Ca(2+) and cell viability of MDCK renal tubular cells. Environ Toxicol Pharmacol. 2017;52:83–9.CrossRef
20.
go back to reference Wu Y, Xu YF, He XJ, Zhang WJ, He Y, Jian MC, et al. Effect of puerarin on relaxation of mesenteric artery in spontaneously hypertensive rats. Chin J Clin Anat. 2019;37:142–7. Wu Y, Xu YF, He XJ, Zhang WJ, He Y, Jian MC, et al. Effect of puerarin on relaxation of mesenteric artery in spontaneously hypertensive rats. Chin J Clin Anat. 2019;37:142–7.
24.
go back to reference Chen G, Pan SQ, Shen C, Pan SF, Zhang XM, He QY. Puerarin inhibits angiotensin II-induced cardiac hypertrophy via the redox-sensitive ERK1/2, p38 and NF-κB pathways. Acta Pharmacol Sin. 2014;35:463–75.CrossRef Chen G, Pan SQ, Shen C, Pan SF, Zhang XM, He QY. Puerarin inhibits angiotensin II-induced cardiac hypertrophy via the redox-sensitive ERK1/2, p38 and NF-κB pathways. Acta Pharmacol Sin. 2014;35:463–75.CrossRef
25.
go back to reference Yuan Y, Zong J, Zhou H, Bian ZY, Deng W, Dai J, et al. Puerarin attenuates pressure overload-induced cardiac hypertrophy. J Cardiol. 2014;63:73–81.CrossRef Yuan Y, Zong J, Zhou H, Bian ZY, Deng W, Dai J, et al. Puerarin attenuates pressure overload-induced cardiac hypertrophy. J Cardiol. 2014;63:73–81.CrossRef
26.
go back to reference Tao Z, Ge Y, Zhou N, Wang Y, Cheng W, Yang Z. Puerarin inhibits cardiac fibrosis via monocyte chemoattractant protein (MCP)-1 and the transforming growth factor-β1 (TGF-β1) pathway in myocardial infarction mice. Am J Transl Res. 2016;8(10):4425–33.PubMedPubMedCentral Tao Z, Ge Y, Zhou N, Wang Y, Cheng W, Yang Z. Puerarin inhibits cardiac fibrosis via monocyte chemoattractant protein (MCP)-1 and the transforming growth factor-β1 (TGF-β1) pathway in myocardial infarction mice. Am J Transl Res. 2016;8(10):4425–33.PubMedPubMedCentral
27.
go back to reference Meng XH, Ni C, Zhu L, Shen YL, Wang LL, Chen YY. Puerarin protects against high glucose-induced acute vascular dysfunction: role of heme oxygenase-1 in rat thoracic aorta. Vasc Pharmacol. 2009;50:110–5.CrossRef Meng XH, Ni C, Zhu L, Shen YL, Wang LL, Chen YY. Puerarin protects against high glucose-induced acute vascular dysfunction: role of heme oxygenase-1 in rat thoracic aorta. Vasc Pharmacol. 2009;50:110–5.CrossRef
28.
go back to reference Shi W, Yuan R, Chen X. Puerarin reduces blood pressure in spontaneously hypertensive rats by targeting eNOS. Am J Chin Med. 2019;47(1):1–20.CrossRef Shi W, Yuan R, Chen X. Puerarin reduces blood pressure in spontaneously hypertensive rats by targeting eNOS. Am J Chin Med. 2019;47(1):1–20.CrossRef
29.
go back to reference Ma JJ, Ma H, Wang YM, Li HM, Pei JM. Vasodilation effect of puerarin on abdominal aortic artery in the rat and the underlying mechanism. Disi Junyi Daxue Xuebao. 2003;24:2231–4. Ma JJ, Ma H, Wang YM, Li HM, Pei JM. Vasodilation effect of puerarin on abdominal aortic artery in the rat and the underlying mechanism. Disi Junyi Daxue Xuebao. 2003;24:2231–4.
31.
go back to reference Gheibi S. S Jeddi, K Kashfi and a Ghasemi. Regulation of vascular tone homeostasis by NO and H2S: implications in hypertension. Biochem. Pharmacol. 2018;149:42–59. Gheibi S. S Jeddi, K Kashfi and a Ghasemi. Regulation of vascular tone homeostasis by NO and H2S: implications in hypertension. Biochem. Pharmacol. 2018;149:42–59.
Metadata
Title
Ameliorated biomechanical properties of carotid arteries by puerarin in spontaneously hypertensive rats
Authors
Xiaoxia Fang
Sheng Dong
Yun Wu
Yun He
Min Lu
Dandan Shi
Na Feng
Songhe Yin
Yan Jiang
Anhua Zhang
Yan Ding
Qiufang Zhang
Junming Tang
Wenjun Zhang
Xiju He
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2021
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-021-03345-8

Other articles of this Issue 1/2021

BMC Complementary Medicine and Therapies 1/2021 Go to the issue